Authors
Bo Xu, Yuichi Saito, Andreas Baumbach, Henning Kelbaek, Niels van Royen, Ming Zheng, Marie-Angele Morel, Paul Knaapen, Ton Slagboom, Thomas W Johnson, Georgios Vlachojannis, Karin E Arkenbout, Lene Holmvang, Luc Janssens, Andrzej Ochala, Salvatore Brugaletta, Christoph K Naber, Richard Anderson, Harald Rittger, Sergio Berti, Emanuele Barbato, Gabor G Toth, Luc Maillard, Christian Valina, Paweł Buszman, Holge Thiele, Volker Schächinger, Alexandra Lansky, William Wijns, TARGET AC Investigators
Publication date
2019/9/9
Journal
JACC: Cardiovascular Interventions
Volume
12
Issue
17
Pages
1679-1687
Publisher
American College of Cardiology Foundation
Description
Objectives
The aim of this study was to assess the 2-year clinical outcomes of the Firehawk stent (Shanghai MicroPort Medical Group, Shanghai, China), a novel abluminal groove–filled biodegradable-polymer sirolimus-eluting coronary stent, compared with XIENCE (Abbott Vascular, Santa Clara, California), a durable-polymer everolimus-eluting coronary stent.
Background
The long-term outcomes of the Firehawk stent have not been evaluated beyond 1 year in a randomized all-comers clinical trial.
Methods
The TARGET All Comers study is a prospective, multicenter, all-comers, randomized, noninferiority trial conducted in Europe. A total of 1,653 patients were randomly assigned to undergo implantation of either the Firehawk or the XIENCE stent. The primary endpoint was target lesion failure, a composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization.
Results …
Scholar articles
B Xu, Y Saito, A Baumbach, H Kelbaek, N van Royen… - JACC: Cardiovascular Interventions, 2019